BLUE
bluebird bio
BLUE
BLUE
Delisted
BLUE was delisted on the 30th of May, 2025.
172 hedge funds and large institutions have $581M invested in bluebird bio in 2021 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 21 increasing their positions, 119 reducing their positions, and 49 closing their positions.
New
Increased
Maintained
Reduced
Closed
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
less capital invested
Capital invested by funds: $ → $
45% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 49
82% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 119
Holders
172
Holding in Top 10
–
Calls
$4.38M
Puts
$6.11M
Top Buyers
| 1 | +$16.5M | |
| 2 | +$7.15M | |
| 3 | +$5.19M | |
| 4 |
Rafferty Asset Management
New York
|
+$3.19M |
| 5 |
Citigroup
New York
|
+$2.77M |
Top Sellers
| 1 | -$45.4M | |
| 2 | -$37.1M | |
| 3 | -$29.9M | |
| 4 |
SC
Sessa Capital
New York
|
-$19.2M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$15.3M |